Inhibitex, Inc. (INHX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Inhibitex, Inc. (INHX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	4/5/2005 8:59:51 PM
	Read Replies (1) of 7

I didn't check to see whether or not Wachovia was one of the underwriters... Inhibitex (INHX) : Wachovia initiates OUTPERFORM. Firm believes there is a high likelihood that the co's lead compound, Veronate, will meet the trial's primary endpoint of a reduction in S. aureus infections. They expect data from the Phase III trial in Q2 2006; 2 DSMB reviews in Spring and Summer to assess powering and event rate in the study could raise investor interest in the meantime. Their valuation range is $11-$13.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next